Roundhill Magnificent Seven ETF vs NeoGenomics Inc. Common Stock — how do they compare? Roundhill Magnificent Seven ETF trades at $72.17 (market cap $5.89B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 2.8× NeoGenomics Inc. Common Stock's market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, NeoGenomics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 35 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| MAGS | NEO | |
|---|---|---|
Market Cap | $5.89B | $2.14B |
Volume | 3,080,349 | 2,228,400 |
Sector | Sector/Thematic | Health |
52-Week High | $74.30 | $19.91 |
52-Week Low | $55.39 | $7.19 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | — | $2.44B |
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $74.30, up 0.43% on the day, with a bullish technical signal driven by moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech stocks, though it has underperformed the S&P 500 in 2026 with a modest 2% year-to-date gain. Recent news highlights the group's focus on AI growth but notes a potential shift in market leadership away from the concentrated 'Magnificent Seven' theme.
The outlook for MAGS hinges on the continued AI-driven performance of its holdings, but risks include high concentration, valuation concerns, and market rotation. Investor sentiment is mixed, with some analysts advocating for the basket approach while others warn of fragmentation. Upside potential exists if the mega-caps reassert dominance, but diversification pressures pose a headwind.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →